Oxford Index Browse

You are looking at 1-10 of 25 items for:

Psychology x Clinical Pharmacology and Therapeutics x clear all

Refine by type

Refine by product

 

antiparkinsonian

Overview page. Subjects: Clinical Pharmacology and Therapeutics — Psychology.

(Of or relating to) any drug that alleviates parkinsonism or the pseudo-parkinsonian side-effects of neuroleptic drugs such as the phenothiazines. In particular, l-dopa or bromocriptine...

See overview in Oxford Index

atomoxetine

Overview page. Subjects: Clinical Pharmacology and Therapeutics — Psychology.

The generic name of a drug for the treatment of attention-deficit/hyperactivity disorder (ADHD), developed by Eli Lilly and first marketed in January 2003. It is administered in the form...

See overview in Oxford Index

Challenges in regulating the use of stimulant drugs for cognitive enhancement in normal individuals

Wayne Hall and John Strang.

in Rethinking Cognitive Enhancement

March 2017; p ublished online April 2017 .

Chapter. Subjects: Clinical Pharmacology and Therapeutics; Neuropsychology. 4853 words.

In this chapter we consider various approaches to regulating the use of putatively cognitively enhancing drugs (CED) such as stimulants. We focus on stimulant drugs (dexamphetamine,...

Go to Oxford Scholarship Online »  abstract

Cognitive enhancement using noninvasive brain stimulation: weighing opportunity, feasibility, and risk

Priyanka P. Shah-Basak and Roy H. Hamilton.

in Rethinking Cognitive Enhancement

March 2017; p ublished online April 2017 .

Chapter. Subjects: Clinical Pharmacology and Therapeutics; Neuropsychology. 12786 words.

Therapies treat diseases, while enhancement improves normal abilities. We have referred to this notion of inorganically boosting the neural functions of healthy individuals as “cosmetic...

Go to Oxford Scholarship Online »  abstract

Debunking the ethical neuroenhancement debate

Stephan Schleim and Boris B. Quednow.

in Rethinking Cognitive Enhancement

March 2017; p ublished online April 2017 .

Chapter. Subjects: Clinical Pharmacology and Therapeutics; Neuropsychology. 5559 words.

In this chapter we argue that the use of stimulant drugs as performance enhancers is neither new nor more common than it was decades ago. Our literature analysis of scientific sources from...

Go to Oxford Scholarship Online »  abstract

Does modafinil improve cognitive functioning in healthy individuals?

Ahmed Dahir Mohamed.

in Rethinking Cognitive Enhancement

March 2017; p ublished online April 2017 .

Chapter. Subjects: Clinical Pharmacology and Therapeutics; Neuropsychology. 8580 words.

This chapter reviews neuropsychopharmacological evidence on the effects of modafinil on cognition in humans. The chapter shows that the cognitive- and attention-enhancing effects of...

Go to Oxford Scholarship Online »  abstract

The effects of Modafinil on creativity: results from a randomized controlled trial

Ahmed Dahir Mohamed.

in Rethinking Cognitive Enhancement

March 2017; p ublished online April 2017 .

Chapter. Subjects: Clinical Pharmacology and Therapeutics; Neuropsychology. 8050 words.

This chapter reports on a randomized controlled trial that investigated the effects of modafinil on divergent and convergent thinking tasks of creativity. Sixty-four healthy volunteers...

Go to Oxford Scholarship Online »  abstract

Enhancement and therapy: is it possible to draw a line?

Alex McKeown.

in Rethinking Cognitive Enhancement

March 2017; p ublished online April 2017 .

Chapter. Subjects: Clinical Pharmacology and Therapeutics; Neuropsychology. 10331 words.

Here I analyze the therapy/enhancement distinction as it relates to pharmaceutical cognitive enhancements claimed to improve capacities such as concentration and memory retention. I also...

Go to Oxford Scholarship Online »  abstract

The ethical debate on human enhancement and cognitive enhancement by way of biotechnologies

Ruud ter Meulen.

in Rethinking Cognitive Enhancement

March 2017; p ublished online April 2017 .

Chapter. Subjects: Clinical Pharmacology and Therapeutics; Neuropsychology. 10538 words.

This chapter presents an overview of the main issues in the ethical debate on the use of biotechnologies to enhance human functioning, including cognitive enhancement technologies. In this...

Go to Oxford Scholarship Online »  abstract

The evolutionary limits to neuroenhancement

Ralph Hertwig and Thomas Hills.

in Rethinking Cognitive Enhancement

March 2017; p ublished online April 2017 .

Chapter. Subjects: Clinical Pharmacology and Therapeutics; Neuropsychology. 6643 words.

In this chapter we focus on the pharmacological enhancement of cognitive traits and ask why traits such as attention and memory have not been more enhanced through evolution. In particular,...

Go to Oxford Scholarship Online »  abstract